DPCA 2-3_entire_v3
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
CPD module<br />
JBS3 Board (2014) Joint British Societies’ consensus recommendations<br />
for the prevention of cardiovascular disease (JBS3). Heart 100:<br />
ii1–1167<br />
Juutilainen A, Kortelainen S, Lehto S et al (2004) Gender difference<br />
in the impact of type 2 diabetes on coronary heart disease risk.<br />
Diabetes Care 27: 2898–904<br />
Kastelein JJ, van der steeg WA, Holme I et al (2008) Lipids,<br />
apolipoproteins, and their ratios in relation to cardiovascular events<br />
with statin treatment. Circulation 117: 3002–9<br />
Keech A, Simes RJ, Barter P et al; FIELD study investigators (2005)<br />
Effects of long-term fenofibrate therapy on cardiovascular events<br />
in 9795 people with type 2 diabetes mellitus (the FIELD study):<br />
randomised controlled trial. Lancet 366: 1849–61<br />
Landray MJ, Reveal Collaborative Group; Bowman L et al (2017)<br />
Randomized Evaluation of the Effects of Anacetrapib through<br />
Lipid-modification (REVEAL) – A large-scale, randomized, placebocontrolled<br />
trial of the clinical effects of anacetrapib among people<br />
with established vascular disease: Trial design, recruitment, and<br />
baseline characteristics. Am Heart J 187: 182–90<br />
National Vascular Disease Prevention Alliance (2012) Absolute<br />
cardiovascular disease risk management. Quick reference guide<br />
for health professionals. National Heart Foundation of Australia.<br />
Available at: http://bit.ly/2tji63M (accessed 19.06.17)<br />
NICE (2014) Cardiovascular disease: Risk assessment and reduction,<br />
including lipid modification (CG181). NICE, London, UK. Available<br />
at: https://www.nice.org.uk/guidance/cg181 (accessed 19.06.17)<br />
Nissen SE, Stroes E, Dent-Acosta Re et al (2016) Efficacy and tolerability<br />
of evolocumab vs ezetimibe in patients With muscle-related statin<br />
intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA 315:<br />
1580–90<br />
Peters SA, Huxley RR, Woodward M (2014) Diabetes as risk factor for<br />
incident coronary heart disease in women compared with men:<br />
a systematic review and meta-analysis of 64 cohorts including<br />
858,507 individuals and 28,203 coronary events. Diabetologia 57:<br />
1542–51<br />
Piepoli M, Hoes AW, Agewall S et al (2016) 2016 European Guidelines<br />
on cardiovascular disease prevention in clinical practice: The Sixth<br />
Joint Task Force of the European Society of Cardiology and Other<br />
Societies on Cardiovascular Disease Prevention in Clinical Practice.<br />
Eur Heart J 37: 2315–81<br />
“The management<br />
of dyslipidaemia in<br />
people with diabetes<br />
should involve a<br />
multifactorial program<br />
to improve lifestyle<br />
and adherence to<br />
treatment.”<br />
Lind M, Bounias I, Olsson M et al (2011) Glycaemic control and<br />
incidence of heart failure in 20,985 patients with type 1 diabetes: An<br />
observational study. Lancet 378: 140–6<br />
Lindsey JB, House JA, Kennedy KF, Marso SP (2009) Diabetes duration<br />
is associated with increased thin-cap fibroatheroma detected by<br />
intravascular ultrasound with virtual histology. Circ Cardiovasc Interv<br />
2: 543–8<br />
Malmberg K, Yusuf S, Gerstein HC et al (2000) Impact of diabetes on<br />
long-term prognosis in patients with unstable angina and non-Qwave<br />
myocardial infarction results of the OASIS (organization to<br />
assess strategies for ischaemic syndromes) registry. Circulation 102:<br />
1014–19<br />
Ross R (1999) Atherosclerosis – an inflammatory disease. N Engl J Med<br />
340: 115–26<br />
Sattar N, Williams K, Sniderman AD et al (2004) Comparison of the<br />
associations of apolipoprotein B and non-high-density lipoprotein<br />
cholesterol with other cardiovascular risk factors in patients with the<br />
metabolic syndrome in the Insulin Resistance Atherosclerosis Study.<br />
Circulation 110: 2687–93<br />
Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident<br />
diabetes: a collaborative meta-analysis of randomised statin trials.<br />
Lancet 375: 735–42<br />
Simons L (2016) Alirocumab and Evolocumab - a new era in cholesterol<br />
control. Medicine Today 17: 51–3<br />
Mazzone T (2007) HDL cholesterol and atherosclerosis. Lancet 370:<br />
107–8<br />
Mazzone T, Chait A, Plutzky J (2008) Addressing cardiovascular disease<br />
risk in diabetes: insights from mechanistic studies. Lancet 371: 180–9<br />
McFadden E, Stevens R, Glasziou P et al (2015) Implications of lower<br />
risk thresholds for statin treatment in primary prevention: Analysis of<br />
CPRD and simulation modelling of annual cholesterol monitoring.<br />
Prev Med 70: 14–16<br />
Mihaylova B, Emberson J, Blackwell L et al (2012) The effects of<br />
lowering LDL cholesterol with statin therapy in people at low<br />
risk of vascular disease: meta-analysis of individual data from 27<br />
randomised trials. Lancet 380: 581–90<br />
Moreno PR, Murcia AM, Palacios IF (2000) Coronary composition and<br />
macrophage infiltration in atherectomy specimens from patients with<br />
diabetes mellitus. Circulation 102: 2180–4<br />
Stroes ES, Thompson PD, Corsini A et al (2015) Statin-associated muscle<br />
symptoms: impact on statin therapy – European Atherosclerosis<br />
Society Consensus Panel Statement on Assessment, Aetiology and<br />
Management. Eur Heart J 36: 1012–22<br />
The Royal Australian College of General Practitioners (2016a)<br />
General practice management of type 2 diabetes: 2016–18.<br />
RACGP, East Melbourne, Vic. Available at: www.racgp.org.au/<br />
your-practice/guidelines/redbook (accessed 23.06.17)<br />
The Royal Australian College of General Practitioners (2016b)<br />
Guidelines for preventive activities in general practice (9 th<br />
edition). RACGP, East Melbourne, Vic. Available at: www.racgp.<br />
org.au/your-practice/guidelines/diabetes (accessed 23.06.17)<br />
Tonkin A, Byrnes A (2014) Treatment of dyslipidemia. F1000 Prime<br />
Reports 6: 17<br />
Vangaveti VN, Shashidhar VM, Rush C et al (2014)<br />
Hydroxyoctadecadienoic acids regulate apoptosis in human<br />
THP-1 cells in a PPARy-dependent manner. Lipids 49: 1181–92<br />
National Heart Foundation of Australia (2015) Heart disease in Australia:<br />
Cardiovascular disease, heart disease and heart attack. Available at:<br />
http://bit.ly/2sGV8Wt (accessed 19.06.17)<br />
National Heart Foundation of Australia, the Cardiac Society of Australia<br />
and New Zealand (2012) Reducing risk in heart disease: an expert<br />
guide to clinical practice for secondary prevention of coronary heart<br />
disease. National Heart Foundation of Australia, Melbourne, Vic.<br />
Available at: http://bit.ly/2sOm33b (accessed 19.06.17)<br />
Virani S (2011) Non-HDL cholesterol as a metric of good quality of care.<br />
Tex Heart Inst J 38: 160–2<br />
Xu J, Zou MH (2009) Molecular insights and therapeutic targets for<br />
diabetic endothelial dysfunction. Circulation 120: 1266–86<br />
Yusuf S, Bosch G, Dagenais J et al (2016) Cholesterol lowering in<br />
intermediate-risk persons without cardiovascular disease. N Engl<br />
J Med 374: 2021–31<br />
Diabetes & Primary Care Australia Vol 2 No 3 2017 109